Amarin (AMRN) Dips Following FDA Orange Book Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
MKM Partners Doesn't See NCE Status or a Quick Sale for Amarin (AMRN)
January 22, 2013 12:47 PM ESTMKM Partners analyst Jon LeCroy commented on Amarin Corporation (NASDAQ: AMRN) Tuesday after an updated Orange Book Cumulative Supplement for December once again failed to rule on NCE status for Vascepa.
LeCroy notes this is the sixth delay to the NCE decision, and they continue to assume that Amarin will be unable to successfully... More
